{
  "meta": {
    "title": "Oncology_Basics_-_2_Oncogenic_Mechanisms",
    "url": "https://brainandscalpel.vercel.app/oncology-basics-2-oncogenic-mechanisms-b5be5410.html",
    "scrapedAt": "2025-11-29T18:25:00.927Z"
  },
  "questions": [
    {
      "id": 19803,
      "choices": [
        {
          "id": 79173,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Non-sense mutation</span></span></span></p>"
        },
        {
          "id": 79174,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Conservative missense mutation</span></span></span></p>"
        },
        {
          "id": 79175,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Non-conservative missense mutation</span></span></span></p>"
        },
        {
          "id": 79176,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Frameshift mutation</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 15-year-old boy presents to the emergency department with severe pain in his lower back and legs. He reports that he has experienced similar pain episodes in the past, usually during times of stress or dehydration. He also mentions that he had a recent upper respiratory infection. On examination, he appears to be in distress due to pain, his temperature is 37.8&deg;C (100&deg;F), and his sclerae are icteric. Laboratory tests reveal a hemoglobin level of 8 g/dL, reticulocyte count of 12%, and elevated bilirubin. Peripheral blood smear shows sickle-shaped red blood cells. Which of the following is the most likely mutation responsible for the condition?</span></span></p>",
      "unique_key": "Q7861876",
      "question_audio": null,
      "question_video": null,
      "map_id": 19806,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans</span></strong><span style=\"font-size:12.0pt\">. <strong>C) Non-conservative missense mutation</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C</span></strong><span style=\"font-size:12.0pt\">:</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient&#39;s presentation is consistent with sickle cell disease, a genetic disorder characterized by the presence of sickle-shaped red blood cells, hemolytic anemia, and vaso-occlusive crises. Sickle cell disease is caused by a non-conservative missense mutation in the HBB gene, which encodes the beta-globin subunit of hemoglobin. Specifically, a single nucleotide substitution (A to T) results in the replacement of glutamic acid with valine at the sixth position of the beta-globin chain (Glu6Val). This amino acid change alters the properties of hemoglobin, leading to the formation of sickle-shaped cells under low oxygen conditions.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><span style=\"font-size:12.0pt\">:</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Non-sense mutation</span></strong><span style=\"font-size:12.0pt\">: This type of mutation introduces a premature stop codon, leading to truncated proteins. It is not the cause of sickle cell disease.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Conservative missense mutation</span></strong><span style=\"font-size:12.0pt\">: This type of mutation changes an amino acid to another with similar properties, which usually does not significantly affect protein function. Sickle cell disease is caused by a non-conservative missense mutation.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Frameshift mutation</span></strong><span style=\"font-size:12.0pt\">: This type of mutation is caused by insertions or deletions that shift the reading frame of the genetic code, resulting in a completely different amino acid sequence downstream. It is not the cause of sickle cell disease.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><span style=\"font-size:12.0pt\">:</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Sickle cell disease is caused by a non-conservative missense mutation in the HBB gene, leading to the substitution of glutamic acid with valine at the sixth position of the beta-globin chain. This mutation alters the properties of hemoglobin, causing red blood cells to assume a sickle shape under low oxygen conditions.</span></span></p>",
      "correct_choice_id": 79175,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19804,
      "choices": [
        {
          "id": 79177,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">HER2/ERBB2 amplification </span></span></span></p>"
        },
        {
          "id": 79178,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">BCR-ABL1 fusion gene </span></span></span></p>"
        },
        {
          "id": 79179,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">CBFB-MYH11 fusion gene </span></span></span></p>"
        },
        {
          "id": 79180,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Polyploidy</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 35-year-old male presents with fatigue, weight loss, and splenomegaly. Blood tests reveal an elevated white blood cell count with a predominance of immature myeloid cells. Cytogenetic analysis of the patient&#39;s bone marrow cells is most likely to reveal which of the following abnormalities?</span></span></span></p>",
      "unique_key": "Q1744292",
      "question_audio": null,
      "question_video": null,
      "map_id": 19807,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans</span></strong><span style=\"font-size:12.0pt\">. <strong>B) BCR-ABL1 fusion gene</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The clinical presentation is suggestive of <strong>chronic myeloid leukemia (CML)</strong>, a myeloproliferative neoplasm characterized by the uncontrolled proliferation of myeloid cells in the bone marrow.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The <strong>BCR-ABL1 fusion gene</strong> is the hallmark of CML, resulting from a reciprocal translocation between chromosomes 9 and 22 (t(9;22)). This fusion gene encodes a constitutively active tyrosine kinase that drives the uncontrolled cell growth. &nbsp; </span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. HER2/ERBB2 amplification</span></strong><span style=\"font-size:12.0pt\"> is associated with breast and other solid tumors. &nbsp; </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. CBFB-MYH11 and FIP1L1-PDGFRA</span></strong><span style=\"font-size:12.0pt\"> are fusion genes associated with other hematological malignancies.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Polyploidy</span></strong><span style=\"font-size:12.0pt\"> refers to an increased number of chromosome sets and is not typically seen in CML.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The BCR-ABL1 fusion gene is a specific genetic abnormality that is highly diagnostic for CML and serves as a target for tyrosine kinase inhibitor therapy</span></span></span></p>",
      "correct_choice_id": 79178,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19805,
      "choices": [
        {
          "id": 79181,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">It promotes cell growth and division </span></span></span></p>"
        },
        {
          "id": 79182,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">It controls proto-oncogene activity </span></span></span></p>"
        },
        {
          "id": 79183,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">It induces angiogenesis </span></span></span></p>"
        },
        {
          "id": 79184,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">It evades apoptosis</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 45-year-old woman presents with a family history of breast and ovarian cancer. Genetic testing reveals a germline mutation in a gene that normally functions to inhibit cell cycle progression and repair DNA damage. Which of the following best describes the role of the affected gene in this patient&#39;s cancer predisposition?</span></span></span></p>",
      "unique_key": "Q3996333",
      "question_audio": null,
      "question_video": null,
      "map_id": 19808,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>B) It controls proto-oncogene activity</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The clinical vignette describes a patient with a likely germline mutation in a tumor suppressor gene, such as BRCA1 or BRCA2. Tumor suppressor genes normally function to regulate cell growth and division, often by inhibiting proto-oncogene activity or promoting DNA repair. Loss of function of these genes, due to inherited or acquired mutations, removes the critical checks on cell growth and can lead to cancer development. &nbsp; </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Promote cell growth and division:</span></strong><span style=\"font-size:12.0pt\"> This is the opposite of what tumor suppressor genes do. They actually inhibit cell growth and division, acting as a brake on the cell cycle.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Induce angiogenesis:</span></strong><span style=\"font-size:12.0pt\"> Angiogenesis (the formation of new blood vessels) is often promoted by cancer cells, not suppressed. Tumor suppressor genes may indirectly inhibit angiogenesis by preventing uncontrolled cell growth.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Evade apoptosis:</span></strong><span style=\"font-size:12.0pt\"> Apoptosis (programmed cell death) is a crucial process for eliminating damaged or abnormal cells. Tumor suppressor genes often promote apoptosis, not evade it.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The primary function of tumor suppressor genes is to control proto-oncogene activity, thereby preventing uncontrolled cell growth and maintaining genomic stability. Inherited mutations in tumor suppressor genes can significantly increase an individual&#39;s risk of developing certain types of cancer. </span></span></span></p>",
      "correct_choice_id": 79182,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19806,
      "choices": [
        {
          "id": 79185,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Ivosidenib</span></span></span></p>"
        },
        {
          "id": 79186,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Romidepsin</span></span></span></p>"
        },
        {
          "id": 79187,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Panobinostat</span></span></span></p>"
        },
        {
          "id": 79188,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Belinostat</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 56-year-old man presents to his primary care physician with a 3-month history of worsening fatigue and unintentional weight loss. His past medical history is significant for hypertension and type 2 diabetes, both well-controlled with medications. He has a 30-pack-year smoking history but quit 10 years ago. Physical examination reveals pallor and generalized lymphadenopathy. Laboratory studies show anemia and thrombocytopenia. A peripheral blood smear demonstrates blast cells. A bone marrow biopsy is performed, and the pathology report indicates acute myeloid leukemia (AML) with a specific chromosomal translocation. Further molecular studies reveal a mutation leading to increased activity of histone deacetylases (HDACs), which is known to be associated with a poor prognosis in this type of leukemia. The oncologist discusses treatment options with the patient, focusing on the potential use of HDAC inhibitors as part of his chemotherapy regimen. Which of the following is not a HDAC inhibitor?</span></span></span></p>",
      "unique_key": "Q9940626",
      "question_audio": null,
      "question_video": null,
      "map_id": 19809,
      "difficulty_level": "difficult",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>A) Ivosidenib</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Ivosidenib is not a histone deacetylase (HDAC) inhibitor. It is actually an inhibitor of the isocitrate dehydrogenase 1 (IDH1) enzyme, which is a different target used in the treatment of certain types of leukemia, particularly those with IDH1 mutations.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B) Romidepsin, C)&nbsp; panobinostat, and D) belinostat</span></strong><span style=\"font-size:12.0pt\"> are all examples of HDAC inhibitors. These drugs work by inhibiting histone deacetylases, which are enzymes involved in the epigenetic regulation of gene expression. By inhibiting these enzymes, HDAC inhibitors can induce cell cycle arrest, differentiation, and apoptosis of cancer cells, making them useful in the treatment of certain hematologic malignancies and solid tumors.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">HDAC inhibitors, such as romidepsin, panobinostat, and belinostat, are used in cancer therapy to inhibit histone deacetylases, leading to epigenetic modulation of gene expression and inducing apoptosis in cancer cells. Ivosidenib, on the other hand, is an IDH1 inhibitor used in the treatment of cancers with IDH1 mutations.</span></span></span></p>",
      "correct_choice_id": 79185,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19807,
      "choices": [
        {
          "id": 79189,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Substitution </span></span></span></p>"
        },
        {
          "id": 79190,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Deletion </span></span></span></p>"
        },
        {
          "id": 79191,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Insertion </span></span></span></p>"
        },
        {
          "id": 79192,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Translocation </span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 40-year-old patient presents with a darkly pigmented skin lesion that has been growing rapidly. A biopsy is performed and the pathology report reveals a malignant melanoma. Further molecular analysis identifies a BRAFV600E Mutation. This specific alteration is best classified as:</span></span></span></p>",
      "unique_key": "Q8098770",
      "question_audio": null,
      "question_video": null,
      "map_id": 19810,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>A) Substitution</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The BRAFV600E mutation, as described in the vignette, is a classic example of a <strong>missense substitution</strong>. It involves the replacement of a single nucleotide in the DNA sequence, leading to a change in the corresponding amino acid in the protein.</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Option</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>B.</strong> Deletions involve the removal of one or more nucleotides from the DNA sequence.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Option</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>C.</strong> Insertions involve the addition of one or more nucleotides to the DNA sequence.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D.</span></strong><span style=\"font-size:12.0pt\"> Translocations involve the rearrangement of genetic material between non-homologous chromosomes.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The BRAFV600E mutation is a common driver mutation in melanoma and is a target for targeted therapy with BRAF inhibitors. Recognizing this type of mutation has important implications for treatment decisions and prognosis in patients with melanoma.</span></span></span></p>",
      "correct_choice_id": 79189,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    }
  ]
}